Scoop: In­Car­da ter­mi­nates its PhI­II tri­al for ar­rhyth­mia drug that was cen­tral to plans for an IPO

In­Car­da Ther­a­peu­tics has ter­mi­nat­ed its Phase III tri­al for an in­haled ver­sion of an ir­reg­u­lar heart­beat drug be­cause of “lim­it­ed ef­fi­ca­cy,” ac­cord­ing to a US …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER